Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
214
-
Total 13F shares, excl. options
-
87M
-
Shares change
-
+5.66M
-
Total reported value, excl. options
-
$6.93B
-
Value change
-
+$483M
-
Put/Call ratio
-
0.75
-
Number of buys
-
122
-
Number of sells
-
-82
-
Price
-
$79.76
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2017
270 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2017.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 214 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87M shares
of 132M outstanding shares and own 66.13% of the company stock.
Largest 10 shareholders include FMR LLC (13.7M shares), WELLINGTON MANAGEMENT GROUP LLP (11.9M shares), DODGE & COX (9.19M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.67M shares), VANGUARD GROUP INC (6.42M shares), BlackRock Inc. (5.19M shares), BAILLIE GIFFORD & CO (3.43M shares), STATE STREET CORP (1.94M shares), PERCEPTIVE ADVISORS LLC (1.83M shares), and GOLDMAN SACHS GROUP INC (1.51M shares).
This table shows the top 214 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.